Screener
Ionis Pharmaceuticals IONS Foreign operations
Foreign operations at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential.
The source filing: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:25 PM EST
- Fiscal year
- FY2026
- Accession
- 0000874015-26-000115
| Pre-tax loss | $(379,601) | ||
| Statutory rate | (79,716) | 21.0% | % |
| State and local income tax, net of federal income tax effect (a) | 353 | (0.1 | )% |
| Foreign tax effects | (118) | 0.0% | % |
| Effect of cross-border tax laws | 459 | (0.1 | )% |
| Changes in unrecognized tax benefits | 12,145 | (3.2 | )% |
| Changes in valuation allowances | 93,773 | (24.7 | )% |
| Tax credits: |
Item 15. Exhibits and Financial Statement Schedules
FAQ
- What is Ionis Pharmaceuticals's foreign operations?
- Ionis Pharmaceuticals (IONS) reported foreign operations of 0% in Q4 2025.
- What does foreign operations mean?
- This metric measures the percentage point impact of foreign income tax rate differentials on the company's total effective tax rate. It provides a normalized view of how international operations influence the overall tax burden compared to the U.S. statutory rate. It helps investors understand the tax-related benefits or risks of the company's global presence.
Ask your AI about Ionis Pharmaceuticals's foreign operations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude